Emergent BioSolutions to Present at Cowen and Company 33rd Annual Health Care Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will provide a corporate overview presentation at the Cowen and Company 33rd Annual...
Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet
Data were published in The Lancet today from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate...
Emergent BioSolutions to Webcast Presentations at February and March 2014 Investor Conferences
During the presentations, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments, preliminary...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2012 on Thursday, March 7, 2013, after market...
Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax
Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax® (Anthrax Vaccine Adsorbed) when administered in...
Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax
Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 2 clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the...
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013
Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2012 financial results and provided guidance for...
Emergent’s TRU-016 for CLL Receives Orphan Medicinal Product Designation from European Commission
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the European Commission granted orphan medicinal product designation to Emergent’s humanized single chain monoclonal antibody against...
Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell...
Emergent BioSolutions to Present at 31st Annual J.P. Morgan Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will provide a corporate overview presentation at the 31st Annual J.P. Morgan Healthcare...
Emergent BioSolutions Appoints Robert G. Kramer as Chief Financial Officer
Emergent BioSolutions (NYSE:EBS) today announced that Robert G. Kramer has been appointed as the company’s chief financial officer effective December 3, 2012. Mr. Kramer succeeds R. Don Elsey, who...
Emergent BioSolutions to Participate in Piper Jaffray’s 24th Annual Healthcare Conference
Emergent BioSolutions Inc. announced today that a member of the company’s senior management team will lead a discussion, which may involve recent business developments and financial results, at the...